REVIMMUNE INC.;NORTHWEST BIOTHERAPEUTICS INC.;COGNATE BIOSERVICES INC.;THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人:
申请号：
IL24533716
公开号：
IL245337D0
申请日:
2016.05.01
申请国别(地区):
IL
年份:
2016
代理人:
摘要：
The present disclosure arises at least in part from the seminal recognition that a combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, or a medically beneficial response by a tumor.
